David Stanton is an associate at Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. David works with biotechnology, pharmaceutical, and life science clients on the development of IP strategy, drafting and prosecuting patent applications, conducting IP due diligence, and working on related business matters. David works with innovators in a variety of technical fields, including genetic and epigenetic editing, cell therapies, immunotherapeutics, pharmaceuticals, and medical devices.
Prior to joining the firm, David earned a Ph.D. in biomedical sciences from West Virginia University, where his doctoral research focused on the development of transcriptional and metabolic dysfunction within peripheral tissues induced by breast cancer growth. During this time, he developed technical expertise in cell and molecular biology, biochemistry, physiology, cancer cell biology, and related fields.
David Stanton is an associate at Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. David works with biotechnology, pharmaceutical, and life science clients on the development of IP strategy, drafting and prosecuting patent applications, conducting IP due diligence, and working on related business matters. David works with innovators in a variety of technical fields, including genetic and epigenetic editing, cell therapies, immunotherapeutics, pharmaceuticals, and medical devices.
Prior to joining the firm, David earned a Ph.D. in biomedical sciences from West Virginia University, where his doctoral research focused on the development of transcriptional and metabolic dysfunction within peripheral tissues induced by breast cancer growth. During this time, he developed technical expertise in cell and molecular biology, biochemistry, physiology, cancer cell biology, and related fields.
- J.D., West Virginia University College of Law, 2025
- Ph.D., Biomedical Sciences, West Virginia University, 2021
- M.S., Exercise Physiology, West Virginia University, 2017
- B.S., Athletic Training, West Virginia Wesleyan College, 2015
- Bar of the District of Columbia
- U.S. Patent and Trademark Office
- J.D., West Virginia University College of Law, 2025
- Ph.D., Biomedical Sciences, West Virginia University, 2021
- M.S., Exercise Physiology, West Virginia University, 2017
- B.S., Athletic Training, West Virginia Wesleyan College, 2015
- Bar of the District of Columbia
- U.S. Patent and Trademark Office
Select Publications
- Co-author with H.E. Wilson, S. Rellick, W. Geldenhuys, and E.E. Pistilli, “Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG,” American Journal of Physiology- Cell Physiology, 2021
- Co-author with H.E. Wilson, C. Montgomery, A.M. Infante, M. Taylor, H. Hazard-Jenkins, E.N. Pugacheva, and E.E. Pistilli, “Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype,” NPJ Breast Cancer, 2020
- Co-author with H.E. Wilson, K.K. Rhodes, D. Rodriguez, I. Chahal, J. Bohlen, M. Davis, A.M. Infante, H. Hazard-Jenkins, D.J. Klinke, E.N. Pugacheva, and E.E. Pistilli, “Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator-activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue,” Clin Cancer Res., 2019
- Co-author with M.J. Myers, D.L. Shepherd, A.J. Durr, J.S. Mohamed, J.M. Hollander, and S.E. Alway, “The role of SIRT1 in skeletal muscle function and repair of older mice,” J Cachexia Sarcopenia Muscle, 2019
- Co-author with S. Haramizu, S. Asano, D.C. Butler, A. Hajira, J.S. Mohamed,and S.E. Alway, “Dietary resveratrol confers apoptotic resistance to oxidative stress in myoblasts,” J Nutr Biochem., 2017
Select Publications
- Co-author with H.E. Wilson, S. Rellick, W. Geldenhuys, and E.E. Pistilli, “Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG,” American Journal of Physiology- Cell Physiology, 2021
- Co-author with H.E. Wilson, C. Montgomery, A.M. Infante, M. Taylor, H. Hazard-Jenkins, E.N. Pugacheva, and E.E. Pistilli, “Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype,” NPJ Breast Cancer, 2020
- Co-author with H.E. Wilson, K.K. Rhodes, D. Rodriguez, I. Chahal, J. Bohlen, M. Davis, A.M. Infante, H. Hazard-Jenkins, D.J. Klinke, E.N. Pugacheva, and E.E. Pistilli, “Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator-activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue,” Clin Cancer Res., 2019
- Co-author with M.J. Myers, D.L. Shepherd, A.J. Durr, J.S. Mohamed, J.M. Hollander, and S.E. Alway, “The role of SIRT1 in skeletal muscle function and repair of older mice,” J Cachexia Sarcopenia Muscle, 2019
- Co-author with S. Haramizu, S. Asano, D.C. Butler, A. Hajira, J.S. Mohamed,and S.E. Alway, “Dietary resveratrol confers apoptotic resistance to oxidative stress in myoblasts,” J Nutr Biochem., 2017
Biological Sciences and Biotechnology
- Antibody
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Immunology
- Molecular biology
- T cell biology
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
Diagnostics and Medical Devices
- Biomedical devices
Genomics and Data Analysis
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- Formulations
- Physical therapy
- Physiology
Biological Sciences and Biotechnology
- Antibody
- Biochemistry
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Immunology
- Molecular biology
- T cell biology
Therapeutics and Drug Discovery
- CRISPR
- Drug delivery
- Gene editing
- Gene therapy
- Immunotherapy targets
Diagnostics and Medical Devices
- Biomedical devices
Genomics and Data Analysis
- shRNA
- Single-cell sequencing
Miscellaneous
- Cancer
- Formulations
- Physical therapy
- Physiology
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
- Privacy Policy
- Terms of Use
- Accessibility